Current basis for discovery and development of aryl hydrocarbon receptor antagonists for experimental and therapeutic...

Area of Science:

• Pharmacology
• Toxicology
• Medicinal Chemistry

Background:

• Aryl hydrocarbon receptor (AhR) activation is implicated in atherosclerosis development from cigarette smoke exposure.
• Existing AhR antagonists have limitations like partial agonism, non-selectivity, and cytotoxicity, hindering clinical progress.
• There is a need for pure, selective, non-toxic, and bioactivation-resistant AhR antagonists.

Purpose of the Study:

• To identify ideal chemical prototypes for developing improved aryl hydrocarbon receptor antagonists.
• To address the limitations of current AhR antagonists in treating atherosclerosis.

Main Methods:

• The study proposes a rational drug design approach based on the aryl hydrocarbon receptor ligand binding domain's structural characteristics.
• Focuses on chlorinated derivatives of trans-stilbene meta-substituted with electrophilic aromatic directing groups.

Main Results:

• Chlorinated trans-stilbene derivatives are proposed as effective prototypes for ideal AhR antagonists.
• These compounds are predicted to be pure, competitive, selective, non-toxic, and resistant to bioactivation.

Conclusions:

• The chemical features of the AhR ligand binding domain can guide the development of pharmacologically superior antagonists.
• Chlorinated trans-stilbene derivatives represent a promising class of compounds for developing novel atheroprotective therapies targeting AhR.